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Alzheimer’s disease (AD), characterized by the abnormal accumulation of amyloid beta
(Aβ), is gradually increasing globally. Given that AD is considered a neuroinflammatory
disease, recent studies have focused on the cellular mechanisms in brain inflammatory
conditions that underlie AD neuropathology. Microglia are macrophage cells in the
central nervous system (CNS) that are activated in response to Aβ condition.
The function of microglia contributes to the neuroinflammation in AD brain, suggesting
that microglia regulate the production of inflammatory mediators and contribute to
the regeneration of damaged tissues. Adiponectin, an adipokine derived from adipose
tissue, has been known to regulate inflammation and control macrophages during
oxidative stress conditions. In present study, we investigated whether adiponectin
influences the polarization and function of microglia under Aβ toxicity by examining
alterations of BV2 microglia function and polarization by Acrp30 (a globular form
of adiponectin) treatment using reverse transcription PCR, western blotting and
immunofluorescence staining. Acrp30 promoted the induction of the M2 phenotype,
and regulated the inflammatory responses through peroxisome proliferator-activated
receptor (PPAR)-γ signaling under Aβ toxicity. In addition, Acrp30 boosted the capacity
of Aβ scavenging in microglia. Taken together, we suggest that adiponectin may control
the function of microglia by promoting anti-inflammatory responses through PPAR-
γ signaling. Hence, we conclude that adiponectin may act as a critical controller of
microglia function in the AD brain.
Keywords: adiponectin, Acrp30, microglia, inflammation, amyloid beta (Aβ), cytokines, peroxisome proliferator-
activated receptor (PPAR)-γ
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia, manifesting as memory
decline and cognitive dysfunction (Bubu et al., 2016; De Strooper and Karran, 2016; Tarantini
et al., 2016). AD is defined by two pathological characteristics: amyloid β-protein (Aβ)
deposition in senile plaques and phosphorylated tau in neurofibrillary tangles (Goate, 2006).
Excessive accumulation of Aβ has been shown to lead to the cognitive impairments in AD
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(Hardy and Selkoe, 2002; Hardy et al., 2014), and has been shown
to trigger inflammation (Del Bo et al., 1995; Combs et al., 2001;
Takata et al., 2003; Lindberg et al., 2005; Kempuraj et al., 2016;
Stamouli and Politis, 2016) through the production of cytokines
and other inflammatory mediators. Several studies of AD brains
reported the presence of activated glial cells around the Aβ
plaques (Mehlhorn et al., 2000; Rogers and Lue, 2001); (uroff,
2017 #365). Microglia, the resident macrophages of the central
nervous system (CNS; Nakamichi et al., 2013; Ginhoux and
Prinz, 2015), constitute 10%–15% of brain cells and play a critical
role in CNS homeostasis (Solé-Domènech et al., 2016). Previous
studies demonstrated that microglia polarizes into two states,
M1 like phenotype and M2 like phenotypes (Francos-Quijorna
et al., 2016; Lee et al., 2016). M1 like phenotype microglia is
related with pro inflammatory response’s induction, whereas
M2 like phenotype microglia is associated with neuroprotective
roles (Eggen et al., 2013; Gertig and Hanisch, 2014; Natoli and
Monticelli, 2014; Plastira et al., 2016; Xu et al., 2016). The
polarization of microglia is important in CNS homeostasis as
it has been shown to affect learning and memory (Tremblay
et al., 2011, 2015; Parkhurst et al., 2013). Numerous studies
have suggested that microglia are activated in the AD brain
and contribute to the prevention of Aβ formation through
phagocytosis of Aβ (Rogers et al., 2002; Doens and Fernández,
2014). Several studies have demonstrated that M2 type microglia
reduce inflammation in the brain (Weekman et al., 2014; Latta
et al., 2015) and ameliorate cognitive dysfunction during Aβ
toxicity (Zhu et al., 2016). These data highlight the necessity to
elucidate the mechanisms underlying Aβ clearance by microglia,
thereby attenuating AD progression. Adiponectin is encoded by
the ADIPOQ gene (Maeda et al., 1996) and exerts multiple effects
by binding to two specific receptors, AdipoR1 and AdipoR2
(Yamauchi et al., 2003; Hug et al., 2004). Adiponectin receptors
exist in various organs, including the liver and brain (Kim
et al., 2013; Kaminski et al., 2014). Previous researches have
demonstrated that adiponectin acts as an insulin sensitizer,
an anti-inflammatory regulator and an anti-atherosclerotic
molecule (Kadowaki et al., 2006; Renaldi et al., 2009). Recent
research has focused on the effect of adiponectin onmacrophages
(Elfeky et al., 2016; Masamoto et al., 2016; Wang et al., 2016);
specifically, that adiponectin may not only act as a key regulator
of inflammatory response in metabolic diseases, but also in CNS
diseases (Wang et al., 2016). In the present study, we investigate
whether adiponectin contributes to the polarization and the
scavenger capacity of microglia under Aβ toxicity. The results
provide significant evidence for the therapeutic potential of




5xFAD male transgenic mice (5 months of age) with detectable
Aβ42 production in the brain were purchased from The
Jackson Laboratory (Bar Harbor, ME). Wild-type male
C57BL/6 mice (25 g, 5 months of age) were provided
by Koatech (Koatech, Pyeongtaek, South Korea). In the
present study, we used four mice in each groups. This study
was carried out in accordance with the recommendations
of ‘‘96 Guidance for Animal Experiments’’, established
by the ‘‘Animal Ethics Committee’’ at Chonnam National
University. The protocol was approved by the ‘‘Animal Ethics
Committee’’ at Chonnam National University, approved
study number 2016-84. The animals were housed in an air-
conditioned room at 25◦C with a 12 h dark/light cycle. All
animals received human care with unlimited access to chow
and water.
Cell Culture and Drug Treatment
Murine BV2 microglial cells were cultured in Dulbecco
Modified Eagle Medium (DMEM; Gibco, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (Gibco),
100 µg/ml penicillin (Gibco) and 100 µg/ml streptomycin
(Gibco). BV2 cells were grown in a humidified incubator
at 37◦C with 5% CO2. The cells were pretreated with
Acrp30 (5 µg/ml; Sigma-Aldrich, St. Louis, MO, USA)
for 24 h and then treated with Aβ (10 µM) for 24 h.
GW9662 was used as the antagonist for PPAR-γ (Chen
et al., 2016). BV2 cells were pretreated with GW9662
(10 µM) for 3 h.
Aβ Oligomer Preparation
Oligomeric Aβ was prepared as previously described (An et al.,
2013). One milligram of synthetic Aβ 42 peptide (American
Peptide, Sunnyvale, CA, USA) was dissolved into 1 ml HFIP
(1,1,1,3,3,3-hexafluoro-2-propanol). The solution should then be
dried under a nitrogen stream. Re-dissolved the remaining film
in 100% HFIP to a concentration of 1 mg/ml. Sonicated in
bath sonicator for 5 min and dried under a nitrogen stream.
Repeated the HFIP treatment twice. Then re-dissolved in 1 ml
HFIP and dried for 2 h. After that the film was resuspended
in 200 ul DMSO to obtain a 1 mM Aβ stock solution. For
10 µM Aβ 42 treatment, 10 ul of Aβ 42 1 mM was dilute
into 10 ml DMEM cell culture media and incubated for
12 h at 37◦C.
Preparation of the AdipoR1 and
AdipoR2 Targeting siRNA
The siRNA for AdipoR1 and AdipoR2 (5 µM) was prepared
to silence AdipoR1 siRNA sc-60123 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and AdipoR2 siRNA sc-46756 (Santa
Cruz Biotechnology). For the transfection of siRNA, a 5 µM
final concentration of siRNAAdipoR1 and siRNAAdipoR2 were
combined with lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) in Opti-MEM medium, and incubated at room
temperature for 20 min. The mixture was added to the BV2 cells
in six well plates. After 2 days, the cells were collected for total
protein or RNA extraction.
Determination of Nitrite
BV2 microglia were seeded onto 96-well plates and pre-treated
with Acrp30 (5 µg/ml) for 24 h prior to stimulation with 10 µM
of Aβ. Supernatants in all groups were measured by nitric oxide
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(NO) production using Griess reagent (Sigma-Aldrich). The
reagents (100 µl) were added to the plate and incubated for
30 min. The absorbance of supernatants was measured at 540 nm
using an ELISA reader (Bio-Rad, Irvine, CA, USA).
ELISA Assay
BV2 cells were plated in 6-well plates (5 × 105 cells/ml) and
incubated with Acrp30 (5 µg/ml) in the presence of Aβ 10 µM
for 24 h. The production of TNF-αwas checked by CymaxMouse
TNF-α ELISA kit (AbFrontier, Seoul, Korea) per manufacturer’s
instructions. The absorbance at 450 nm was assessed by ELISA
(Bio-Rad).
Phagocytosis Assay
The phagocytosis assay was conducted using the Cayman
chemical phagocytosis kit (Cayman Chemical, Ann Arbor, MI,
USA). To check opsonization of target particles, all phagocytosis
assays were conducted in complete DMEM media. Additionally,
in some experiments, labeled particles were preopsonized by
incubation at 37◦C for 3 h with 5 mg/mL immunoglobulin G
(IgG; Beletskii et al., 2005; Cayman Chemical).
Western Blot Analysis
The BV2 cells were washed with phosphate-buffered saline (PBS)
and collected. Cell pellets were lysed with ice-cold RIPA buffer
(Sigma-Aldrich). The lysates were centrifuged at 15,900 g for
30 min at 4◦C to produce whole-cell extracts. Protein (30 µg)
in cells was separated on a 10% SDS-polyacrylamide gel and
transferred onto a polyvinylidene difluoride membrane. After
blocking with 5% skim milk prepared in Tris-buffered saline-
Tween (20 nM Tris [pH 7.2], 150 mM NaCl, 0.1% Tween 20) for
1 h, 30 min at room temperature, immunoblots were incubated
for 18 h at 4◦C with primary antibodies that detect AdipoR1
(1:1000, Abcam, Cambridge, MA, USA), AdipoR2 (1:1000,
Abcam, Cambridge, MA, USA), CD86 (1:1000, Cell Signaling,
Danvers, MA, USA), p-NF-κB (1:1000, Cell Signaling), PPAR-γ
(1:1000, Cell Signaling, Danvers, MA), p-PPAR-γ (1:1000, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and β-actin (1:1000;
Millipore, Billerica, MA, USA). All blots were then incubated
with appropriate secondary antibodies (Abcam, Cambridge, MA,
USA) for 1 h 30 min at room temperature. All blots were
visualized using ECL solution (Millipore, Billerica, MA, USA).
Quantitative Real-Time PCR
To examine the amount of CD86, CD206, iNOS and TNF-α
mRNA in BV2 cells, quantitative real-time PCR was performed
using each primer. Cellular RNA was extracted from BV2 cells
using Trizol reagent (Invitrogen). RNA was mixed with One
Step SYBRr Prime Script TM RT-PCR Kit II (Takara, Otsu,
Shiga, Japan) and specific primers in a total reaction volume of
50 µl. PCR was performed using the following each primers (5′
to 3′): CD86 (F): GTA TTT TGG CAG GAC CAG GA, (R): GCC
GCT TCT TCT TCT TCC AT, CD206 (F): GAG GGA AGC
GAG AGA TTA TGG A, (R): GCC TGA TGC CAG GTT AAA
GCA, iNOS (F): GGG AAT CTT GGA GCG AGT TG, (R): GTG
AGG GCT TGG CTG AGT GA, TNF-α (F): CGT CAG CCG
FIGURE 1 | The expression of CD86 and Iba-1 in 5xFAD mouse brain.
(A) Western blotting band showed increased CD86 protein level in the 5xFAD
mouse brain. Data are expressed as mean ± SEM. Each experiment was
conducted three times per condition. β-actin served as a control. Differences
were considered statistically significant at ∗p < 0.05 (compared to control).
Immunofluorescence images showed increased expression of CD86 (B) and
Iba-1 (C) in the cortex and striatum of the 5xFAD mouse brain. Scale bar:
50 µm, Con: normal mouse, 5xFAD: 5xFAD mouse, CD86: green, Iba-1:
green, 4′,6-diamidino-2-phenylindole (DAPI): blue.
ATT TGC TAT CT, (R): CGG ACT CCG CAA AGT CTA AG,
GAPDH (F): GAC AAG CTT CCC GTT CTC AG, (R): GAG
TCAACGGATTTGGTCGT. Amplification cycles were carried
out at 52◦C for 5 min, 95◦C for 10 s, 95◦C for 5 s, 58◦C for
35 s and 65◦C for 15 s. Quantitative SYBR Green real time PCR
was performed with Takara PCR System (Takara, Otsu, Shiga,
Japan). GAPDH was used as an internal control. The∆Ct values
of treated cells were compared to those of normal, control cells
(Popivanova et al., 2008).
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FIGURE 2 | The expression of CD86 and CD206 in amyloid beta (Aβ)-treated BV2 microglia. The mRNA level of CD86 (A) and CD206 (B) was detected by
RT PCR. Data are expressed as mean ± SEM. Each experiment was conducted three times per condition. GAPDH served as a control. Differences were considered
statistically significant at ∗p < 0.05 (compared to control). (C) Immunofluorescence images showed the reduction of CD86 by Acrp30 pretreatment in Aβ- exposed
BV2 microglia. Acrp30: Acrp30 5 µg/ml pretreatment, Aβ: Aβ 10 µM treatment for 24 h, Scale bar: 100 µm, CD86: green, 4′,6-diamidino-2-phenylindole (DAPI): blue.
Reverse Transcription PCR
Total RNA in BV2 cells was isolated using Trizol Reagent
(Gibco). RT-PCR reaction was conducted by using the Invitrogen
One step IIITM Reverse Transcription PCR kit (Invitrogen).
cDNA synthesis from mRNA and sample normalization were
conducted. PCR was performed using the following thermal
cycling conditions: 95◦C for 10 min;, 40 cycles of denaturing
at 95◦C for 15 s, annealing at 60◦C for 30 s, elongation at
72◦C for 30 s, final extension at 72◦C for 5 min and holding
at 4◦C. PCR was performed using the following primers
(5′ to 3′): AdipoR1 (F): CCCACCATGCACTTTACTAT,
(R) CACCATAGAAGTGGACGAAA, AdipoR2 (F): CAACC
TTGCTTCATCTACCT, (R): CTAGCCATAAGCATTAGCCA,
CD36 (F): GAG CCA TCT TTG AGC CTT CA, (R): TCA GAT
CCG AAC ACA GCG TA, PPAR- γ (F): CAA TCC GAA TTT
TTC AAG GGT GCC A, (R): GAG CAC CTT GGC GAA CAG
CTG AGA G, iNOS (F): GGG AAT CTT GGA GCG AGT TG,
(R): GTG AGG GCT TGG CTG AGT GA, TNF-α (F): CGT
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FIGURE 3 | The expression of adiponectin receptors in BV2 microglia. The mRNA levels of AdipoR1 (A) and AdipoR2 (B) were measured by RT-PCR.
The protein levels of AdipoR1 (C) and AdipoR2 (D) were detected by western blotting analysis. Data are expressed as mean ± SEM. Each experiment was
conducted three times per condition. β- actin served as a control. Differences were considered statistically significant at ∗p < 0.05, ∗∗p < 0.001 (compared to
control). Acrp30: Acrp30 5 µg/ml pretreatment, Aβ: Aβ 10 µM treatment for 24 h.
CAG CCG ATT TGC TAT CT, (R): CGG ACT CCG CAA AGT
CTA AG, GAPDH (F): GAC AAG CTT CCC GTT CTC AG,
(R): GAG TCA ACG GAT TTG GTC GT. PCR products were
electrophoresed in 1% agarose gels. All samples were normalized
with GAPDH.
Immunocytochemistry
BV2 cells were washed with PBS and permeabilized for 20 min
with 4% paraformaldehyde (Sigma-Aldrich). The cells were
incubated with the primary antibodies overnight at 4◦C. The
primary antibody anti-rabbit CD86 (1:500, Cell Signaling) as a
marker of M1 phenotype microglia (Gong et al., 2016) was used.
After incubation, BV2 cells were washed twice with PBS and
incubated with specific secondary antibody for 1 h 30 min at
room temperature. The cells were counterstained with 1 µg/ml
4′,6-diamidino-2-phenylindole (DAPI, 1:100, Invitrogen) for
10min at room temperature. Images were obtained using an LSM
520 confocal microscope (Carl Zeiss, Thornwood, NY, USA).
Immunohistochemistry
Brain sections (20 µm) were mounted onto coated glass slides
(Thermo Scientific, Waltham, MA, USA), and fixed in cold
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FIGURE 4 | The expression of pro-inflammatory mediators in Aβ-treated BV2 microglia. (A) The production of nitric oxide (NO) was assessed by Griess
reagent assay. Acrp30 reduced the production of NO in Aβ-treated microglia. The increased mRNA level of iNOS (B) and IL-6 (C) and TNF-α (D) were measured by
RT PCR. Data are expressed as mean ± SEM. Each experiment was conducted four times per condition. GAPDH served as a control. Differences were considered
statistically significant at ∗p < 0.05. ∗∗p < 0.001 (compared to control). Acrp30: Acrp30 5 µg/ml pretreatment, Aβ: Aβ 10 µM treatment for 24 h.
acetone for 10 min at −20◦C. The slides were washed in
Tris-buffered saline and incubated with 0.3% H2O2 in methanol.
To block nonspecific labeling, sections were incubated in 5%
bovine serum albumin (Sigma-Aldrich) and diluted in PBS for
80 min before the addition of primary and secondary antibody.
Primary antibodies for anti-rabbit CD86 (1:100, Cell Signaling)
and anti-rabbit Iba-1 (1:100, Cell Signaling) were applied to the
samples overnight at 4◦C, followed by 1 h 30min incubation with
appropriate florescence secondary antibody (1:100, Millipore),
and three washes in PBS for 5 min each. After three washes in
0.1% PBS with Tween-20 (PBST), the sections were incubated
with secondary antibody for 1 h 30 min in the dark at room
temperature. After three washes in PBS, all sections were
incubated with 1 µg/ml DAPI (Sigma-Aldrich, St. Louis, MO,
USA) and visualized under a LSM 520 confocal microscope
(Carl Zeiss).
Statistical Analysis
The data were analyzed by SPSS 18.0 software (IBM Corp.,
Armonk, NY, USA). All results are expressed asmean± standard
deviation (SD). Statistical significance was determined using
one-way analysis of variance (ANOVA) followed by Turkey’s
multiple comparison and Student’s t-test. Differences were
considered statistically significant at p< 0.05.
RESULTS
The Activation and Polarization of
Microglia in AD Mouse Brain
To confirm the activation of microglia in the mouse brain,
we detected the protein level of CD86 as a marker of
activated microglia using western blot (Figure 1A), and the
expression of CD86 and Iba-1 using immunohistochemistry
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FIGURE 5 | The expression of pro-inflammatory mediators by suppressing AdipoR1 in Aβ-treated BV2 microglia. The reduced mRNA level of TNF-α
(A) and iNOS (B) and TNF-α (C) in Aβ-treated microglia were assessed by RT PCR. (C) The reduced production of TNF-α by Acrp30 in Aβ-treated microglia was
increased by blocking AdipoR1. Data are expressed as mean ± SEM. Each experiment was conducted four times per condition. GAPDH served as a control.
Differences were considered statistically significant at ∗p < 0.05. ∗∗p < 0.001 (compared to control). Acrp30: Acrp30 5 µg/ml pretreatment, Aβ: Aβ 10 µM treatment
for 24 h.
(Figures 1B,C). Our data showed higher activation of microglia
(increased CD86 protein level and a greater percentage of
CD86 and Iba-1 positive cells) in the AD compared to the
control mouse brain (Figures 1A–C). These results suggest
that microglia are activated in an AD brain with Aβ
accumulation. To assess the polarization of microglia with
Aβ treatment and Acrp30 (a globular form of adiponectin)
pretreatment, we assessed the mRNA level of CD86 as a
marker of M1 phenotype microglia and of CD206 as a marker
of M2 phenotype microglia (Figure 2). The mRNA level of
CD206 was reduced while the mRNA level of CD86 was
markedly increased in Aβ-exposed microglia (Figures 2A,B).
Acrp30 reduced the expression of CD86 and increased the
expression of CD206 in BV2 microglia (Figures 2A,B).
Furthermore, Acrp30 pretreatment reduced CD86 mRNA
level and increased CD206 mRNA level in spite of Aβ
treatment (Figures 2A,B). Immunostaining data showed a
decrease in CD86 expression in Aβ-exposed microglia with
Acrp30 pretreatment (Figure 2C).
The Activation and Polarization of
Microglia in AD Mouse Brain
To examine the changes of adiponectin receptors in microglia
under Aβ toxicity, we conducted reverse transcriptional PCR
(Figures 3A,B) and western blotting (Figures 3C,D). The
mRNA levels (Figures 3A,B) and protein levels (Figures 3C,D)
of AdipoR1 and AdipoR2 were reduced in Aβ-treated microglia.
Acrp30 promoted the expression of AdipoR1, whereas
Acrp30 did not meaningfully change the expression of AdipoR2,
in Aβ-treated microglia (Figures 3A,B). Notably, the protein
level of AdipoR1 in microglia was decreased by Aβ treatment
(Figure 3C).
Acrp30 Treatment Leads to the Reduced
Expression of Pro-Inflammatory Mediators
in Aβ-Exposed Microglia
To examine alterations in the expression of pro-inflammatory
mediators by Acrp30, we assessed the production of NO
using the Griess assay (Figure 4A) and the mRNA of iNOS
(Figure 4B). Moreover, we detected the mRNA level of IL-6
and TNF-α as pro-inflammatory cytokines using real time PCR
in microglia (Figures 4C,D). Acrp30 treatment did not change
the level of NO, iNOS, IL-6, or TNF-α in BV2 microglia,
whereas the expression of these pro-inflammatory mediators
were increased in Aβ-treated microglia. Acrp30 pretreatment
led to a decrease in NO, iNOS, IL-6 and TNF-α in Aβ-treated
microglia (Figures 4A–D).
Acrp30 Reduced the Expression of TNF-α
and iNOS in Aβ-Exposed Microglia
To test for the expression of TNF-α and iNOS in Aβ-exposed
microglia, we detected mRNA levels using reverse transcription
PCR (Figure 5). The mRNA level of TNF-α in microglia under
Aβ toxicity was significantly increased, while the mRNA level
of TNF-α in Aβ-treated microglia was considerably reduced
by Acrp30 pretreatment (Figure 5A). When we inhibited the
expression of AdipoR1 using siRNA AdipoR1, we observed an
increase in TNF-αmRNA level in Aβ-exposed microglia in spite
of Acrp30 pretreatment (Figure 5A). In addition, the mRNA
levels of iNOS and TNF-α showed the same expression patterns
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FIGURE 6 | The measurement of phagocytosis ability in Aβ-treated
BV2 microglia. Images showing the ability of phagocytosis in BV2 microglia.
The green color shows the beads for determining the ability of phagocytosis in
Aβ-treated microglia. Scale bar: 200 µm, Bead particles: green.
(Figure 5B), and the secretion of TNF-α and TNF-α mRNA
level demonstrated similar patterns (Figure 5C). The knockdown
of AdipoR1 did not reduce the expression of pro-inflammatory
mediators (Figure 5).
Acrp30 Increases the Ability of
Phagocytosis in Aβ Exposed Microglia
To examine the phagocytotic ability of microglia, we conducted
the phagocytosis assay (Figure 6). Aβ-exposed microglia showed
that the green beads were phagocytosed in many microglia.
Acrp30 were increased the phagocytosis ability of microglia in Aβ
toxicity (Figure 6). Thus, adiponectin promoted the phagocytosis
ability of microglia in Aβ toxicity.
Acrp30 Controls PPAR-γ Signaling in Aβ
Exposed Microglia
To examine whether Acrp30 influences the expression of
PPAR-γ in Aβ-treated microglia, we conducted real time PCR
(Figure 7). The mRNA level of CD36 (a scavenger receptor for
FIGURE 7 | The expression of CD36 and PPAR-γ in Aβ treated
BV2 microglia. The mRNA levels of CD36 (A) and PPAR-γ (B) were checked
by RT PCR. The reduced mRNA levels of CD36 and PPAR-γ by Acrp30 in Aβ
treated microglia were increased by inhibiting AdipoR1. Data are expressed as
mean ± SEM. Each experiment was conducted four times per condition.
GAPDH served as a control. Differences were considered statistically
significant at ∗p < 0.05 (compared to control). Acrp30: Acrp30 5 µg/ml
pretreatment, Aβ: Aβ 10 µM treatment for 24 h, siAdipoR1: siRNA
AdipoR1 transfection.
phagocytosis) was markedly increased in Aβ-treated microglia
(Figure 7A). Acrp30 attenuated the expression of CD36 in
microglia under Aβ toxicity (Figure 7A). The mRNA level
of PPAR-γ was increased in Aβ treated microglia, while
Acrp30 reduced the expression of PPAR-γ in microglia under
Aβ toxicity (Figure 7B). To test whether Acrp30 directly
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FIGURE 8 | The change in PPAR-γ signaling by inhibiting AdipoR1 in Aβ-treated BV2 microglia. The protein levels of CD86 (A) and p-NF-κB (B) p-PPAR-γ
(C) protein were detected by western blotting analysis. (C) The decreased p-PPAR-γ protein level by Acrp30 and GW9662 in Aβ-treated microglia was not changed
by suppressing AdipoR1. Data are expressed as mean ± SEM. Each experiment was conducted four times per condition. GAPDH served as a control. Differences
were considered statistically significant at ∗p < 0.05 (compared to control). Acrp30: Acrp30 5 µg/ml pretreatment, Aβ: Aβ 10 µM treatment for 24 h, siAdipoR1:
siRNA AdipoR1 transfection, GW9662: PPAR-γ antagonist 10 µM. ∗∗p < 0.001.
regulates the PPAR-γ signaling in Aβ treated microglia, we
examined CD86, p- NF-κB and PPAR-γ protein levels using
western blotting analysis (Figure 8) and tested the effect
of the PPAR-γ antagonist GW9662 in Aβ-treated microglia
(Figure 8). Our results showed that GW9662 reduces the protein
level of CD86 in spite of Aβ-treatment (Figure 8A). Reduced
CD86 protein level in Aβ treated microglia with GW9662 was
increased by inhibiting AdipoR1 (Figure 8A). The blocking
of AdipoR1 reduced the function of PPAR-γ (decreased the
expression of CD86) in Aβ-treated microglia (Figure 8A). In
addition, GW9662 reduced the phosphorylation of NF-κB in
spite of Aβ-treatment (Figure 8B). Reduced protein level of p-
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NF-κB in Aβ-treated microglia with GW9662 was increased by
inhibiting AdipoR1 (Figure 8B). The protein level of PPAR-γ
in Aβ-treated microglia was reduced by Acrp30 and GW 9662,
whereas the protein level of PPAR-γ in Aβ-treatedmicroglia with
GW9662 was not changed by inhibition of AdipoR1 (Figure 8C).
Based on our results, Acrp30 attenuated PPAR-γ signaling in
microglia by mediating AdipoR1.
DISCUSSION
AD is characterized by the abnormal accumulation of Aβ and
chronic neuroinflammation (Ramanathan et al., 2015; Scheltens
et al., 2016). Clearance of Aβ and chronic inflammation are
related to the polarization of and phagocytotic ability of
microglia (Ide et al., 1996; Heese et al., 1998; Hutchinson
et al., 2009; Tang and Le, 2016). The M2 phenotype microglia
have been demonstrated to have a neuroprotective function
in AD (Zhu et al., 2016). A recent study showed that
M2 macrophage transplantation reduces neuroinflammation in
the brain, promotes clearance of Aβ, and improves cognitive
impairment (Zhu et al., 2016). Aβ and tau oligomers activate
M1 pro-inflammatory responses and induce irreversible neuron
loss (Tang and Le, 2016). The M1 phenotype microglia secrete
pro-inflammatory mediators including TNF-α, IL-6 and NO,
whereas anti-inflammatory M2 phenotype microglia produce
anti-inflammatory mediators such as IL-10 and IL-4 under
oxidative stress conditions (Tang and Le, 2016). In this study,
we examined the alteration of cytokine expression by Acrp30 in
Aβ-treated microglia. We found that adiponectin attenuates the
expression of pro-inflammatory cytokines, and AdipoR1 may
mediate the function of adiponectin secretion of inflammatory
cytokines, considering that the expression of pro-inflammatory
cytokines was not reduced in Aβ-treated microglia despite
Acrp30 pretreatment.
In the present study, we found activated microglia in vivo
in the AD mouse brain and in vitro under Aβ–induced
inflammatory conditions. Increased expression of CD86, a
known M1 receptor marker (Gong et al., 2016) was found in
the cortex and striatum of 5xFAD mice, and in Aβ-treated
BV2 microglia. Based on our results, we suggest that adiponectin
might promote the polarization of M2 type microglia under
Aβ toxicity conditions. Moreover, our results showed that
adiponectin activates M2 phenotype microglia (Lovren et al.,
2010). Increased CD206 and reduced M1 polarization was
demonstrated by the reduction of pro-inflammatory cytokines
such as TNF-α and IL-6, and the reduction of CD86 and iNOS
expression.
Adiponectin regulates many processes by binding with
specific receptors, AdipoR1 and AdipoR2 (Hug et al.,
2004) and exists in various organs, including the brain
(Kaminski et al., 2014). We observed more expression of
AdipoR1 than AdipoR2 in BV2 microglia under Aβ induced
toxicity. Previous studies demonstrated that downregulation
of AdipoR1 attenuates anti-inflammatory responses (Zhang
et al., 2016) and reduces the adiponectin’s beneficial actions
in macrophages (Luo et al., 2013). We observed that the
downregulation of AdipoR1 by siRNA AdipoR1 increases
pro-inflammatory cytokines including TNF-α and iNOS
production under Aβ toxicity in spite of Acrp30 pretreatment.
Judging from our results, we assume that the inhibitory effect of
adiponectin in pro-inflammatory cytokine production may be
mediated by AdipoR1.
Fibrillar Aβ has been reported to interact with the cell
surface receptor and leads to intracellular signaling, and then
stimulates phagocytosis (D’Andrea et al., 2004; Mohamed and
Posse de Chaves, 2011). CD36, one of the class B scavenger
receptors, has been shown to be expressed in various cell types
and bind with diverse ligands (Febbraio et al., 2001), and to
participate in the internalization of numerous small particles,
including Aβ (Koenigsknecht and Landreth, 2004) and apoptotic
cells (Fadok et al., 1998). CD36 has been shown to uptake
Aβ (Moore et al., 2002), and is involved in the production of
pro-inflammatory mediators (Janabi et al., 2000; Stuart et al.,
2005; Baranova et al., 2008). Several studies have demonstrated
that CD36 boosts pro-inflammatory responses (Janabi et al.,
2000; Moore et al., 2002; Okamura et al., 2009; Silverstein and
Febbraio, 2009) and phagocytosis (Erdman et al., 2009). Studies
have also shown that the activation of macrophages promotes
the expression of CD36 by generation of ligands of PPAR-γ
(Huang et al., 1999; Berry et al., 2007) and adiponectin inhibits
the expression of scavenger receptor CD36 (Ouchi et al., 2001).
Based on the current results, we hypothesize that adiponectin can
attenuate the expression of CD36, leading to the production of
pro-inflammatory cytokines.
Moreover, previous studies have demonstrated that PPAR-γ
can mediate the conversion of the microglia phenotype
(Yamanaka et al., 2012; Saijo et al., 2013). Our results indicate
that PPAR-γ may induce M2 phenotype microglia under
Aβ toxicity via adiponectin treatment. Several studies have
demonstrated that PPAR-γ agonists alleviate neuroinflammation
in AD models by acting as anti-inflammatory regulators
(Ghisletti et al., 2007; Saijo et al., 2013) while others have
shown that PPAR-γ can regulate the secretion of inflammatory
cytokines in microglia, ultimately promoting tissue repair
(Chawla, 2010; Chinetti-Gbaguidi et al., 2011).
In the present study, we found that adiponectin may
contribute to the function and polarization of microglia through
PPAR-γ signaling. In particular, adiponectin may play a pro-
inflammatory role through PPAR-γ bymediating AdipoR1. Even
though we did not present evidence on memory improvement
by adiponectin through PPAR-γ in AD brain, we speculate
that adiponectin may improve memory in AD by attenuating
PPAR-γ signaling in microglia, and regulate the function of
microglia under Aβ toxicity by regulating PPAR-γ through
AdipoR1.
Taken together, we conclude that: (1) adiponectin may induce
the M2 polarization of microglia in Aβ toxicity; (2) adiponectin
may regulate the production of pro-inflammatory cytokines
by mediating AdipoR1 under Aβ toxicity; and (3) adiponectin
may exert anti-inflammatory functions in microglia and regulate
the polarization of microglia through PPAR-γ signaling under
Aβ toxicity. Thus, we suggest that adiponectin is a crucial
adipokine to attenuate AD pathology by regulating the function
of microglia.
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